Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

17.85 +1.62 (+9.99%)
Streaming Delayed Price Updated: 12:16 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Recap: KalVista Pharma Q3 Earnings ↗
 
Via Benzinga
News headline image
Insiders Buying Dorian LPG And 2 Other Stocks ↗
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? ↗
Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Insiders Buying Monro And 3 Other Stocks ↗
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks ↗
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗
Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.